Difference between revisions of "Sonidegib (Odomzo)"
(Created page with "==General information== Class/mechanism: Hedgehog pathway inhibitor. Sonidegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog...") |
|||
| Line 13: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *7/24/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm Initial FDA approval] "for the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy."<ref name="insert"></ref> | + | *7/24/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm Initial FDA approval] "for the treatment of patients with locally advanced [[Basal_cell_and_squamous_cell_skin_cancer|basal cell carcinoma (BCC)]] that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy."<ref name="insert"></ref> |
==Also known as== | ==Also known as== | ||
Revision as of 21:44, 27 July 2015
General information
Class/mechanism: Hedgehog pathway inhibitor. Sonidegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 7/24/2015: Initial FDA approval "for the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy."[1]
Also known as
Erismodegib, LDE225